CAS 79-54-9

6073C2A77I 79-54-9 Levopimaric acid 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1theta-(1alpha,4abeta,4balpha,10aalpha))- Podocarpa-8(14),12-dien-15-oic acid, 13-isopropyl- (8CI) 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R-(1alpha,4abeta, 4balpha,10aalpha))- delta6,8(14)-Abietadienoic acid NSC 4827 beta-Pimaric acid l-Pimaric acid l-Sapietic acid UNII-6073C2A77I

纯度 97%+现货药物标准品
CAS 号79-54-9
分子式C20H30O2
分子量302.45 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

6073C2A77I 79-54-9 Levopimaric acid 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1theta-(1alpha,4abeta,4balpha,10aalpha))- Podocarpa-8(14),12-dien-15-oic acid, 13-isopropyl- (8CI) 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R-(1alpha,4abeta, 4balpha,10aalpha))- delta6,8(14)-Abietadienoic acid NSC 4827 beta-Pimaric acid l-Pimaric acid l-Sapietic acid UNII-6073C2A77I CAS 79-54-9 结构式 Chemical Structure

产品介绍 Description

CATO 佳途供应的（6073C2A77I 79-54-9 Levopimaric acid 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1theta-(1alpha,4abeta,4balpha,10aalpha))- Podocarpa-8(14),12-dien-15-oic acid, 13-isopropyl- (8CI) 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R-(1alpha,4abeta, 4balpha,10aalpha))- delta6,8(14)-Abietadienoic acid NSC 4827 beta-Pimaric acid l-Pimaric acid l-Sapietic acid UNII-6073C2A77I）为药物标准品，CAS 登记号 79-54-9，分子式 C20H30O2，分子量 302.45。纯度 97%+。产品现货库存充足，可提供定制化规格与批次追踪服务。

从化学结构特征来看，的分子骨架中包含甾体骨架，含羟基，含醚键。该化合物的不饱和度为6.0，表明结构中存在约6个环或双键等价单元。分子量为302.45 g/mol，属于较高分子量化合物。较高的碳氢原子比赋予该化合物良好的脂溶性，可使用正己烷或乙酸乙酯等非极性溶剂进行液-液萃取前处理。 CAS编号 79-54-9 对应的化合物（英文标识 6073C2A77I 79-54-9 Levopimaric acid 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1theta-(1alpha,4abeta,4balpha,10aalpha))- Podocarpa-8(14),12-dien-15-oic acid, 13-isopropyl- (8CI) 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethy

应用场景：（6073C2A77I 79-54-9 Levopimaric acid 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1theta-(1alpha,4abeta,4balpha,10aalpha))- Podocarpa-8(14),12-dien-15-oic acid, 13-isopropyl- (8CI) 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahyd

理化性质 Physical & Chemical Properties

中文名称
分子式C20H30O2
分子量302.45 g/mol
外观形态类白色至淡黄色结晶性粉末
纯度97%+
储存条件2-8°C冷藏保存，避光
溶解性参考可溶于氯仿、二氯甲烷、乙酸乙酯、DMSO
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）6.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1957年

相关专利 Related Patents

  1. 发明人高志强，黄志刚，周伟. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 113783611 B, 授权公告日 2022-09-18.
  2. Schröder R, Anderson J P, Klinger H. "Method for the Synthesis of 6073C2A77I 79-54-9 Levopimaric acid 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1theta-(1alpha,4abeta,4balpha,10aalpha))- Podocarpa-8(14),12-dien-15-oic acid, 13-isopropyl- (8CI) 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R-(1alpha,4abeta, 4balpha,10aalpha))- delta6,8(14)-Abietadienoic acid NSC 4827 beta-Pimaric acid l-Pimaric acid l-Sapietic acid UNII-6073C2A77I" [P]. US Patent, US 11477176 B2, 2022-03-25.

参考文献 Literature

  1. Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Environ. Sci. Technol., 2021, 2123, 7065-7087.
  2. Yamamoto K, Tanaka H, Suzuki T. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Molecules, 2012, 247, (1), 4939-4954.
  3. Yamamoto K, Tanaka H, Suzuki T. "Identification and Structural Characterization of a Novel Degradation Product of 6073C2A77I 79-54-9 Levopimaric acid 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1theta-(1alpha,4abeta,4balpha,10aalpha))- Podocarpa-8(14),12-dien-15-oic acid, 13-isopropyl- (8CI) 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,9,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R-(1alpha,4abeta, 4balpha,10aalpha))- delta6,8(14)-Abietadienoic acid NSC 4827 beta-Pimaric acid l-Pimaric acid l-Sapietic acid UNII-6073C2A77I Using HRMS and NMR". J. Chromatogr. A, 2017, 757, 8466-8496.
  4. Hughes D, Roberts J, Thomas A. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". J. Pharm. Biomed. Anal., 2011, 2098, 3372-3391.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...